Abbvie's | search
Click here to view Abbvie's news from 60+ newspapers.
Bookmark or Share- U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults ...VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease. Adults treated with VYALEV reported superior improvement in " on" time without troublesome dyskinesia, compared to oral immediate-release carbidopa/levodopa1.
- Pharmaceutical Research & Development | AbbVieAbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
- Pipeline | AbbVie - Pharmaceutical Research & DevelopmentABBV-113 is an oral NLRX1 agonist (a member of the NOD-like receptor family) being investigated for treatment of ulcerative colitis. NLRX1 regulates immunometabolism and inflammation, and its activation may address inflammatory bowel disease (IBD) pathogenesis. Potential Indication. Phase 1 Phase 2 Phase 3 Status. i.
- Investor Overview | AbbVieAnswers to questions concerning AbbVie stock purchase, dividends, and how to contact AbbVie's transfer agent and Investor Relations.
- Our Principles - AbbVieWe strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.
More
